The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Interventions for preventing neuropathy caused by cisplatin and related compounds
Open accessAbstract
BACKGROUND: Cisplatin and several related antineoplastic drugs used to treat many types of solid tumours are neurotoxic, and most patients completing a full course of cisplatin chemotherapy develop a clinically detectable sensory neuropathy. Effective neuroprotective therapies have been sought. OBJECTIVES: To examine the efficacy and safety of purported chemoprotective agents to prevent or limit the neurotoxicity of cisplatin and related drugs. SEARCH METHODS: On 4 March 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and CINAHL Plus for randomised trials designed to evaluate neuroprotective agents used to prevent or limit neurotoxicity of cisplatin and related drugs among human patients. SELECTION CRITERIA: We included randomised controlled trials (RCTs) or quasi-RCTs in which the participants received chemotherapy with cisplatin or related compounds, with a potential chemoprotectant (acetylcysteine, amifostine, adrenocorticotrophic hormone (ACTH), BNP7787, calcium and magnesium (Ca/Mg), diethyldithiocarbamate (DDTC), glutathione, Org 2766, oxcarbazepine, or vitamin E) compared to placebo, no treatment, or other treatments. We considered trials in which participants underwent evaluation zero to six months after completing chemotherapy using quantitative sensory testing (the primary outcome) or other measures including nerve conduction studies or neurological impairment rating using validated scales (secondary outcomes). DATA COLLECTION AND ANALYSIS: Two review authors assessed each study, extracted the data and reached consensus, according to standard Cochrane methodology. MAIN RESULTS: As of 2013, the review includes 29 studies describing nine possible chemoprotective agents, as well as description of two published meta-analyses. Among these trials, there were sufficient data in some instances to combine the results from different studies, most often using data from secondary non-quantitative measures. Nine of the studies were newly included at this update. Few of the included studies were at a high risk of bias overall, although often there was too little information to make an assessment. At least two review authors performed a formal review of an additional 44 articles but we did not include them in the final review for a variety of reasons.Of seven eligible amifostine trials (743 participants in total), one used quantitative sensory testing (vibration perception threshold) and demonstrated a favourable outcome in terms of amifostine neuroprotection, but the vibration perception threshold result was based on data from only 14 participants receiving amifostine who completed the post-treatment evaluation and should be regarded with caution. Furthermore the change measured was subclinical. None of the three eligible Ca/Mg trials (or four trials if a single retrospective study was included) described our primary outcome measures. The four Ca/Mg trials included a total of 886 participants. Of the seven eligible glutathione trials (387 participants), one used quantitative sensory testing but reported only qualitative analyses. Four eligible Org 2766 trials (311 participants) employed quantitative sensory testing but reported disparate results; meta-analyses of three of these trials using comparable measures showed no significant vibration perception threshold neuroprotection. The remaining trial reported only descriptive analyses. Similarly, none of the three eligible vitamin E trials (246 participants) reported quantitative sensory testing. The eligible single trials involving acetylcysteine (14 participants), diethyldithiocarbamate (195 participants), oxcarbazepine (32 participants), and retinoic acid (92 participants) did not perform quantitative sensory testing. In all, this review includes data from 2906 participants. However, only seven trials reported data for the primary outcome measure of this review, (quantitative sensory testing) and only nine trials reported our objective secondary measure, nerve conduction test results. Additionally, methodological heterogeneity precluded pooling of the results in most cases. Nonetheless, a larger number of trials reported the results of secondary (non-quantitative and subjective) measures such as the National Cancer Institute Common Toxicity Criteria (NCI-CTC) for neuropathy (15 trials), and these results we pooled and reported as meta-analysis. Amifostine showed a significantly reduced risk of developing neurotoxicity NCI-CTC (or equivalent) ≥ 2 compared to placebo (RR 0.26, 95% CI 0.11 to 0.61). Glutathione was also efficacious with an RR of 0.29 (95% CI 0.10 to 0.85). In three vitamin E studies subjective measures not suitable for combination in meta analysis each favoured vitamin E. For other interventions the qualitative toxicity measures were either negative (N-acetyl cysteine, Ca/Mg, DDTC and retinoic acid) or not evaluated (oxcarbazepine and Org 2766).Adverse events were infrequent or no
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Levi-Montalcini, R., & Angeletti, P. U. (1968) · Physiological Reviews · doi:10.1152/physrev.1968.48.3.534 · Cited by 2,016
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_6514 · Cited by 1,385
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Cisplatin (cis-diamminedichloroplatinum II)
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions
Gamelin, L., Boisdron‐Celle, M., Delva, R., Guerin‐Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0666 · Cited by 385
Dyck, P. J., Davies, J. L., Litchy, W. J., & O'Brien, P. C. (1997) · Neurology · doi:10.1212/wnl.49.1.229 · Cited by 382
Peripheral sensory neuropathy and cisplatin chemotherapy
Roelofs, R. I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984) · Neurology · doi:10.1212/wnl.34.7.934 · Cited by 370
Toxic effects of cis-dichlorodiammineplatinum(II) in man.
Hoff, V., Schilsky, R. L., Reichert, C. M., Rl, R., Rozencweig, M., Rc, Y., & Muggia, F. M. (1980) · PubMed · Cited by 336
Oxaliplatin-safety profile: neurotoxicity
GROTHEY, A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00399-3 · Cited by 319
Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy
Pace, A., Savarese, A., Picardo, M., Maresca, V., Pacetti, U., Del Monte, G., Biroccio, A., Leonetti, C., Jandolo, B., Cognetti, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.139 · Cited by 307
Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds329 · Cited by 293
Self-citationPrevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., Elderson, A., Boogerd, W., Heimans, J. J., Vries, E. P., van Houwelingen, J. C., Jennekens, F. G. I., Gispen, W. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 287
Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., & Bidoli, P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.008 · Cited by 274
Self-citationLissoni, P., Barni, S., Mandalà, M., Ardizzoia, A., Paolorossi, F., Vaghi, M., Longarini, R., Malugani, F., & Tancini, G. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00159-8 · Cited by 253
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
Wang, W.-S., Lin, J.-K., Lin, T.-C., Chen, W.-S., Jiang, J.-K., Wang, H.-S., Chiou, T.-J., Liu, J.-H., Yen, C.-C., & Chen, P.-M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-312 · Cited by 210
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial
Argyriou, A. A., Chroni, E., Koutras, A., Ellul, J., Papapetropoulos, S., Katsoulas, G., Iconomou, G., & Kalofonos, H. P. (2005) · Neurology · doi:10.1212/01.wnl.0000148609.35718.7d · Cited by 209
Grothey, A., Nikcevich, D. A., Sloan, J. A., Kugler, J. W., Silberstein, P. T., Dentchev, T., Wender, D. B., Novotny, P. J., Chitaley, U., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5911 · Cited by 198
Clinical Management of Oxaliplatin-Associated Neurotoxicity
Grothey, A. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.s.006 · Cited by 192
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.574 · Cited by 192
Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial
Pace, A., Giannarelli, D., Galiè, E., Savarese, A., Carpano, S., Della Giulia, M., Pozzi, A., Silvani, A., Gaviani, P., Scaioli, V., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5279e · Cited by 191
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
Pisano, C., Pratesi, G., Laccabue, D., Zunino, F., Giudice, P. L., Bellucci, A., Pacifici, L., Camerini, B., Vesci, L., Castorina, M., et al. (2003) · PubMed · Cited by 181
Self-citationSmyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., & Tedeschi, M. (1997) · Annals of Oncology · doi:10.1023/a:1008211226339 · Cited by 178
Corticotropin-Releasing Hormone
Taylor, A. L., & Fishman, L. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807283190405 · Cited by 176
Kottschade, L. A., Sloan, J. A., Mazurczak, M. A., Johnson, D. B., Murphy, B. P., Rowland, K. M., Smith, D. A., Berg, A. R., Stella, P. J., & Loprinzi, C. L. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-010-1018-3 · Cited by 173
Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164
Self-citationMollman, J. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220210 · Cited by 163
Cascinu, S., Cordella, L., Ferro, E. D., Fronzoni, M., & Catalano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.26 · Cited by 158
Culy, C. R., & Spencer, C. M. (2001) · Drugs · doi:10.2165/00003495-200161050-00012 · Cited by 152
Argyriou, A. A., Chroni, E., Koutras, A. K., Iconomou, G., Papapetropoulos, S., Polychronopoulos, P., & Kalofonos, H. P. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0072-3 · Cited by 138
A review of oxaliplatin and its clinical use in colorectal cancer
Grothey, A. A., & Goldberg, R. M. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.10.2159 · Cited by 127
Lin, P., Lee, M.-Y., Wang, W.-S., Yen, C., Chao, T., Hsiao, L., Yang, M., Chen, P., Lin, K., & Chiou, T.-J. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0018-9 · Cited by 125
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub3 · Cited by 104
Self-citationCarozzi, V., Canta, A., Oggioni, N., Sala, B., Chiorazzi, A., Meregalli, C., Bossi, M., Marmiroli, P., & Cavaletti, G. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.09.004 · Cited by 101
Self-citationTreatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin
Lissoni, P., Tancini, G., Barni, S., Paolorossi, F., Ardizzoia, A., Conti, A. M. F., & Maestroni, G. J. M. (1997) · Supportive Care in Cancer · doi:10.1007/bf01262569 · Cited by 100
Planting, A. S. T., Catimel, G., Mulder, P. H. M. D., de Graeff, A., Höppener, F., Verweij, I., Oster, W., & Vermorken, J. B. (1999) · Annals of Oncology · doi:10.1023/a:1008353505916 · Cited by 99
Tomiwa, K., Nolan, C., & Cavanagh, J. (1986) · Acta Neuropathologica · doi:10.1007/bf00688308 · Cited by 98
Schmidt, Y., Unger, J. W., Bartke, I., & Reiter, R. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90054-3 · Cited by 81
Thalidomide neuropathy in patients treated for metastatic prostate cancer
Molloy, F. M., Floeter, M. K., Syed, N. A., Sandbrink, F., Culcea, E., Steinberg, S. M., Dahut, W. L., Pluda, J. M., Kruger, E. A., Reed, E., et al. (2001) · Muscle & Nerve · doi:10.1002/mus.1109 · Cited by 81
Moore, D. H., Donnelly, J. P., McGuire, W. P., Almadrones, L., Cella, D. F., Herzog, T. J., & Waggoner, S. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.086 · Cited by 80
Arrieta, O. G., Hernández‐Pedro, N., Aragón, M. C. F.-G., Saavedra-Pérez, D., Campos-Parra, A. D., Ríos-Trejo, M. Á., Cerón-Lizárraga, T., Martínez-Barrera, L. M., Pineda, B., Ordóñez, G., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822e045c · Cited by 80
Milla, P., Airoldi, M., Weber, G., Drescher, A., Jaehde, U., & Cattel, L. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832a2dc1 · Cited by 76
Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Dr, G., Perez, E. A., Weibe, et al. (1991) · PubMed · Cited by 75
Gandara, D. R., Nahhas, W. A., ADELSON, M. D., Lichtman, S. M., Podczaski, E. S., Yanovich, S., Homesley, H. D., Braly, P. D., Ritch, P. S., & Weisberg, S. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.490 · Cited by 74
Hilpert, F., Stähle, A., Tomé, O., et al. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0782-y · Cited by 70
Ishibashi, K., Okada, N., Miyazaki, T., Sano, M., & Ishida, H. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0015-3 · Cited by 68
Reich, C. J. (1972) · PubMed · Cited by 62
Clinical trials of WR-2721 and cis-platinum
Glover, D. J., Grabelsky, S. A., Fox, K. R., et al. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90283-6 · Cited by 59
The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo
Hovestadt, A., van der Burg, M. E. L., Verbiest, H. B. C., van Putten, W. L. J., & Vecht, C. J. (1992) · Journal of Neurology · doi:10.1007/bf00833914 · Cited by 56
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub2 · Cited by 54
Self-citationProtection against oxaliplatin acute neurosensory toxicity by venlafaxine
Durand, J.-P., Brézault, C., & Goldwasser, F. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200307000-00006 · Cited by 53
Wen, F., Zhou, Y., Wang, W., Hu, Q., Liu, Y. T., Zhang, P. F., Du, Z., Dai, J., & Li, Q. (2012) · Annals of Oncology · doi:10.1093/annonc/mds211 · Cited by 49
Capizzi, R. L., & Oster, W. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00144-8 · Cited by 47
Weekly cisplatin ± glutathione in relapsed ovarian carcinoma
Colombo, N., BINI, S., Miceli, D. D., Bogliun, G., Marzorati, L., Cavaletti, G., Parmigiani, F., Venturino, P., Tedeschi, M., Frattola, L., et al. (1995) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1995.05020081.x · Cited by 44
Self-citationBlock, K. I., & Gyllenhaal, C. (2005) · Integrative Cancer Therapies · doi:10.1177/1534735405282842 · Cited by 37
van Gerven, J., Hovestadt, A., Moll, J. W. B., et al. (1994) · Journal of Neurology · doi:10.1007/bf00900961 · Cited by 34
Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose, P. S. (1996) · PubMed · Cited by 34
Lissoni, P., Vaghi, M. M., Ardizzoia, A., Malugani, F., Fumagalli, E. R., Bordin, V., Fumagalli, L., Bordoni, A., Mengo, S., Gardani, G., et al. (2002) · PubMed · Cited by 29
ACTH/MSH like peptides in the treatment of cisplatin neuropathy
Gispen, W. H., Hamers, F. P. T., Vecht, C. J., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90205-w · Cited by 28
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial
Pace, A., Bove, L., & Jandolo, B. (2005) · Neurology · doi:10.1212/wnl.65.3.501 · Cited by 28
Cited by
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Self-citationChemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Metadata
- Authors
- Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-03-31
- Volume
- 2014
- Issue
- 3
- Pages
- CD005228-CD005228
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2101160724
- Cited by
- 298
- References
- 65
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.